In the trial analysis we found that serum Wnt Inhibitory Factor 1 and endothelial cell-specific molecule 1 (endocan) were increased with weight-loss, though these proteins were not consistently associated with BMI at baseline and follow-up genetic analyses did not identify any effects of serum Wnt Inhibitory Factor 1 or endothelial cell-specific molecule 1 on type 2 diabetes-related cancer risk. This evidence concerns the gene ESM1 and cancer.